Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Grivas P, Bellmunt J, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Blake-Haskins JA, Laliberte RJ, Wang J, Costa N, Powles T May 13, 2022 AUA 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up Results From the JAVELIN Bladder 100 Trial

View Presentation View Abstract Plain Language Summary
Poster
Mehlhaff B, Shore ND, George DJ, Cookson MS, Saltzstein DR, Tutrone R, Bailen JL, Brown B, Langenberg AGM, Fallick M, Lu S, Hanson S, Tombal B, Saad F May 14, 2022 AUA 2022 Prostate Cancer

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis From the Randomized Phase 3 HERO Study

View Presentation View Abstract Plain Language Summary
Poster
Shore ND, Iguchi T, Villers A, Azad AA, Szmulewitz RZ, Holzbeierlein J, Alcaraz A, Alekseev B, Gomez-Veiga F, Rosbrook B, Lee H-J, Haas GP, Armstrong AJ, Stenzl A May 14, 2022 AUA 2022 Prostate Cancer

Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated With Enzalutamide or Placebo Plus Androgen Deprivation Therapy who had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial

View Presentation View Abstract Plain Language Summary
Poster
Lowentritt B, Fallick M, Dufour R, Pruett J, Jiang T, Nwokeji E, Nagao M May 15, 2022 AUA 2022 Prostate Cancer

Evaluating Cardiovascular Risk in Men Starting Androgen Deprivation Therapy for Prostate Cancer

View Presentation View Abstract Plain Language Summary
Oral Presentation
Bailen JL, Saad F, George DJ, Mehlhaff B, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Langenberg AGM, Lu S, Lee J, Hanson S,  Tombal B, Shore ND May 15, 2022 AUA 2022 Prostate Cancer

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies

View Presentation View Abstract Plain Language Summary